ANL 13.70 Decreased By ▼ -0.10 (-0.72%)
ASC 14.92 Increased By ▲ 0.36 (2.47%)
ASL 15.21 Decreased By ▼ -0.09 (-0.59%)
AVN 101.46 Increased By ▲ 1.57 (1.57%)
BOP 8.56 Decreased By ▼ -0.04 (-0.47%)
CNERGY 6.80 Decreased By ▼ -0.21 (-3%)
FFL 9.34 Decreased By ▼ -0.15 (-1.58%)
FNEL 9.12 Decreased By ▼ -0.27 (-2.88%)
GGGL 14.26 Decreased By ▼ -0.64 (-4.3%)
GGL 22.01 Decreased By ▼ -0.11 (-0.5%)
GTECH 10.08 Increased By ▲ 0.11 (1.1%)
HUMNL 6.66 No Change ▼ 0.00 (0%)
KEL 3.21 Decreased By ▼ -0.05 (-1.53%)
KOSM 4.25 Decreased By ▼ -0.13 (-2.97%)
MLCF 33.60 Decreased By ▼ -0.44 (-1.29%)
PACE 4.20 Decreased By ▼ -0.15 (-3.45%)
PIBTL 7.35 Decreased By ▼ -0.05 (-0.68%)
PRL 14.56 Decreased By ▼ -0.34 (-2.28%)
PTC 8.97 Decreased By ▼ -0.13 (-1.43%)
SILK 1.37 Decreased By ▼ -0.04 (-2.84%)
SNGP 34.15 Decreased By ▼ -0.35 (-1.01%)
TELE 18.43 Increased By ▲ 0.68 (3.83%)
TPL 14.90 Decreased By ▼ -0.45 (-2.93%)
TPLP 29.50 Decreased By ▼ -0.40 (-1.34%)
TREET 40.25 Decreased By ▼ -0.76 (-1.85%)
TRG 90.75 Decreased By ▼ -3.60 (-3.82%)
UNITY 27.50 Decreased By ▼ -0.70 (-2.48%)
WAVES 15.42 Decreased By ▼ -0.11 (-0.71%)
WTL 2.30 Decreased By ▼ -0.05 (-2.13%)
YOUW 8.00 Decreased By ▼ -0.22 (-2.68%)
BR100 4,657 Decreased By -21.1 (-0.45%)
BR30 18,291 Decreased By -332.3 (-1.78%)
KSE100 45,387 Decreased By -120.1 (-0.26%)
KSE30 17,876 Decreased By -49.8 (-0.28%)

coronavirus
Coronavirus
VERY HIGH
Source: covid.gov.pk
Pakistan Deaths
29,037
824hr
Pakistan Cases
1,338,993
5,47224hr
Sindh
509,308
Punjab
455,499
Balochistan
33,744
Islamabad
112,557
KPK
182,619

LONDON: British regulators on Thursday approved a GlaxoSmithKline drug to treat those at high risk of developing severe Covid-19 symptoms, with the manufacturer saying it appears effective against the new Omicron variant.

The antibody treatment, sotrovimab, "was found to be safe and effective at reducing the risk of hospitalisation and death in people with mild to moderate COVID-19 infection who are at an increased risk of developing severe disease," said the Medicines and Healthcare products Regulatory Agency (MHRA).

Preclinical data showed that the drug "retains activity against key mutations of the new Omicron SARS-CoV-2 variant," GlaxoSmithKline (GSK) said in a statement.

First known UAE case of Omicron variant detected in fully vaccinated traveller

"To date, sotrovimab has demonstrated ongoing activity against all tested variants of concern and interest defined by the World Health Organization (WHO)," it added.

Testing is ongoing "to confirm the neutralising activity of sotrovimab against the combination of all the Omicron mutations with the intent to provide an update by the end of 2021."

A single dose of the drug was found to reduce the risk of hospitalisation and death by 79 percent in high-risk adults with symptomatic COVID-19 infection, according to the MHRA.

Sotrovimab was developed by Britain's GSK and Vir Biotechnology based out of California.

First Omicron case in US fuels global alarm over virus variant

It is a monoclonal antibody, a type of protein that attaches to the spike protein of the coronavirus, reducing its ability to enter the body's cells.

Comments

Comments are closed.